[BillionToOne Sequel] Stock Price Soars After IPO—The Path to a Ten-Bagger Mapped by 'Molecular Counting' Technology and the Real Intentions of Institutional Investors

In November 2025, BillionToOne, Inc. (hereinafter referred to as BillionToOne or the Company)'s initial public offering (IPO) on the NASDAQ market was not merely a capital-raising event, but was etched into the market as a turning point for valuation standards in the precision medicine sector. The proprietary molecular counting technology, "Quantitative Counting Templates (QCT)," deployed by the company overcomes the limitations of probabilistic noise inherent in traditional next-generation sequencing (NGS), establishing a new standard of "absolute quantification" in the fields of prenatal diagnostics and liquid biopsy.

This report provides a thorough verification based on available data and disclosure documents regarding the post-IPO stock price performance, multifaceted evaluations by Wall Street analysts, market penetration of the flagship UNITY platform, and the progress of the Northstar cancer diagnostic product line, which serves as the next growth engine. In particular, we will delve into the structural advantages and potential risk factors that justify why BillionToOne can command a "premium valuation" within the competitive landscape against incumbent giants such as Natera (NTRA) and Guardant Health (GH).